

**February 24-25, 2017**

24 February-08.00-17.00

25 February-09.00-17.00

**İTÜ Maslak Campus**

Süleyman Demirel Kültür Merkezi

### Organising Committee

- Prof. Dr. Philip Paty
- Prof. Dr. Rob Glynn-Jones
- Prof. Dr. Geerard L. Beets
- Prof. Dr. Regina Beets-Tan
- Prof. Dr. Oktar Asoğlu
- Prof. Dr. Ayhan Kuzu
- Prof. Dr. Cem Terzi
- Prof. Dr. Selman Sökmen
- Prof. Dr. Türker Bulut
- Prof. Dr. Duygu Derin
- Assoc. Prof. Merdan Fayda
- Assoc. Prof. Banş Bakır
- Assoc. Prof. Handan Tokmak
- Assist. Prof. Meltem Selam Topalgökçeli
- Assist. Prof. Burçin Batman
- Assist. Prof. Çiğdem Arslan

**To Attent:** Burçin Öztürk

+90 552 411 65 22

[burcin.ozturk@livhospital.com.tr](mailto:burcin.ozturk@livhospital.com.tr)



Memorial Sloan-Kettering  
Cancer Center



**liv**  
HOSPITAL

**V. SYMPOSIUM**

LIV HOSPITAL & MSKCC

# Non-Operative Management of Rectal Cancer: A New Standard of Care

## DAY ONE

08.30-09.00: Opening Ceremony

09.00-09.30: Key Note Lecture I - Moderator : Nil Molinas, Dursun Buğra

What we have learned from TME: Achievements and limitations in the cure of rectal cancer. 30' - Ayhan Kuzu

09.30-10.00: Key Note Lecture II - Neoadjuvant therapy and its impact on the radicalism of surgery: past, present, and future. 30' - Rob Glynne -Jones

10.00-10.30: Key Note Lecture III - The evolving role of MRI in rectal cancer: what have we learned and what is next? 30' Regina Beets-Tan

10.30-11.45: Session I: Outcomes of TME: Innocent or Guilty? - Moderator : Tahsin Çolak İsmail Hamzaoğlu

\* Bowel Function after Rectal Cancer Surgery (LAR Syndrome—good or bad?) 15' - İlker Sücüllü

\* Urinary and sexual dysfunction: what, when, and why? 15' - Emre Balık

\* Managing CRM involvement on the MR? On the surgical specimen? 15' - Ersin Öztürk

\* Anastomotic leakage and the impact on oncologic outcome. 15' - Mustafa Öncel

\* Discussion 15'

11.45-13.00: Lunch

13.00-14.30: Session II: Assessing the response to neoadjuvant treatment? - Moderator : Gökhan Demir, Ethem NeziH Oral

\* What is the definition of clinical complete response? Why is it important? 20' - Türker Bulut

\* Can MR imaging select and predict clinical complete response? 20' - Regina Beets-Tan

\* Is pathologic assessment necessary in clinical complete response: Biopsy, Local Excision, TME or nothing? 20' - Geerard L Beets

\* What is the role of PET/CT assessing the response to neoadjuvant treatment? 20' - Handan Tokmak

\* Discussion 10'

14.30-15.00: Coffee break

15.00-17.00: Session III: Who are candidates for "Watch and Wait" (W&W) strategy?

Moderator : Sümer Yamaner, Süha Göksel

\* Are there clinical or molecular predictors of response? Are they helpful? 15' - Geerard Beets

\* Clinical Stage I rectal cancer: TME versus chemoradiotherapy: Avoiding surgery or overtreatment. 15' - Selman Sökmen

\* Is W+W an option for more advanced (Bulky, cT4, or cN2) rectal cancers? 15' - Philip Paty

\* Case Discussion Panel (Theme: what patients should be offered W+W) 75'

Presenter : Oktar Asoğlu & Barış Bakır

Panelists : Philip Paty , Geerard L Beets, Regina Beets-Tan, Rob Glynne -Jones, Funda Obuz, Selman Sökmen, Süha Göksel , Özlem Er

## DAY TWO

09.00-10.00: Session IV: Watch and Wait - Cemil Aliyev, Uğur Selek

MSKCC Experience 20' - Philip Paty

The Maastricht/Dutch Experience 20' - Geerard L Beets

İstinye University/Liv Hospital Experience 20' - Oktar Asoğlu

Discussion 10'

10.00-10.30: Coffee break

10.30-12.30: Session V: Can we increase clinical complete response rate? - Moderator: Funda Obuz, Süleyman Altun

\* Enhancing response to radiotherapy for W&W strategy? 20' - Rob Glynne-Jones

\* How long should we wait for obtaining the optimal response? 20' Cem Terzi

\* Induction and consolidation chemotherapy in W+W strategy 20' Duygu Derin

\* Case discussion panel (Borderline or unusual W+W cases; how to implement W+W) 60'

Presenter :Oktar Asoğlu – Barış Bakır

Panelists : Philip Paty, Geerard L. Beets, Cem Terzi, Rob Glynne-Jones, Funda Obuz, Burak Şakar,

Handan Tokmak, Yersu Kapran, Barış Bakır

12.30-12.45: Roche Sempozyumu Moderator: Duygu Derin

\* Biological therapies for rectal cancer 15' Gökhan Demir

12.45-13:45: Lunch

13.45-15.05: Session VI: My patient has a CCR and wants W+W. Now what? Moderator: Ayşe Mudun, Nuran Beşe

\* Is W+W a standard approach? What do I tell the patient? 20' Geerard L Beets

\* What is optimal follow-up plan for W+W 20' Oktar Asoğlu

\* Distant metastases and late local re-growths during W+W: Should we be worried? 20' Philip Paty

\* Discussion 20'

15.05-15.30: Coffee break

15.30-17.00: Session VII: Management of incomplete responses and local re-growths- Moderator: Sarımbek Navruzov, Mustafa Ünsal

\* The “near” complete response: Radical surgery, local excision, or continued observation? 15' Philip Paty

\* Treatment of local re-growths: What are the options? 15' Ayhan Kuzu

\* Can longer chemotherapy prevent distant metastases and increase survival? 15' Sezer Sağlam

\* Case discussion panel (Follow-up, outcomes, and salvage treatment for W+W cases) 50'

Presenter: Oktar Asoğlu, Barış Bakır

Panelists : Ayhan Kuzu, Philip Paty, Geerard L Beets, Rob Glynne-Jones , Sezer Sağlam, Handan Tokmak, Yersu Kapran,

Funda Obuz, Başak Oyan Uluç

17.00-17.30: Take home message panel

Moderator : Turker Bulut

Panelist: Philip Paty , Geerard L Beets , Ayhan Kuzu, Cem Terzi , Oktar Asoğlu, Selman Sökmen,

Rob Glynne- Jones, Merdan Fayda, Funda Obuz, Süha Göksel, Barış Bakır, Duygu Derin , Handan Tokmak